1.915
price down icon1.79%   -0.035
 
loading
前日終値:
$1.95
開ける:
$1.95
24時間の取引高:
1.35M
Relative Volume:
0.31
時価総額:
$860.87M
収益:
-
当期純損益:
$-75.80M
株価収益率:
-5.4714
EPS:
-0.35
ネットキャッシュフロー:
$-68.07M
1週間 パフォーマンス:
-6.59%
1か月 パフォーマンス:
-9.67%
6か月 パフォーマンス:
-28.01%
1年 パフォーマンス:
-39.40%
1日の値動き範囲:
Value
$1.88
$1.95
1週間の範囲:
Value
$1.81
$2.10
52週間の値動き範囲:
Value
$1.54
$3.97

Nuvation Bio Inc Stock (NUVB) Company Profile

Name
名前
Nuvation Bio Inc
Name
セクター
Healthcare (1174)
Name
電話
(415) 754-3517
Name
住所
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Name
職員
273
Name
Twitter
Name
次回の収益日
2025-03-05
Name
最新のSEC提出書
Name
NUVB's Discussions on Twitter

NUVB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NUVB
Nuvation Bio Inc
1.9135 860.87M 0 -75.80M -68.07M -0.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
449.77 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
530.20 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.76 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
562.99 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.03 28.51B 3.81B -644.79M -669.77M -6.24

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-23 開始されました Citizens JMP Mkt Outperform
2024-03-27 アップグレード Jefferies Hold → Buy
2024-03-26 アップグレード BTIG Research Neutral → Buy
2023-01-06 ダウングレード Jefferies Buy → Hold
2022-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-08-02 ダウングレード BTIG Research Buy → Neutral
2022-05-04 開始されました H.C. Wainwright Buy
2021-10-15 再開されました BTIG Research Buy
2021-04-06 開始されました RBC Capital Mkts Outperform
2021-03-08 開始されました BMO Capital Markets Outperform
2021-03-08 開始されました BTIG Research Buy
2021-03-08 開始されました Cowen Outperform
2021-03-08 開始されました Jefferies Buy
2021-03-08 開始されました Wedbush Outperform
すべてを表示

Nuvation Bio Inc (NUVB) 最新ニュース

pulisher
Jun 18, 2025

Insider Buying: Stacy Markel Acquires 10,000 Shares of Nuvation Bio Inc (NUVB) - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 17, 2025

Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Nuvation Bio (NUVB) Target Price Revised Amid Commercial Shift | NUVB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk - MarketScreener

Jun 17, 2025
pulisher
Jun 16, 2025

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire

Jun 16, 2025
pulisher
Jun 13, 2025

Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Nuvation Bio stock holds steady as FDA approves lung cancer drug - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Nuvation Bio price target maintained at $6 by Citizens JMP - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 12, 2025

FDA Approves Nuvation Bio’s Ibtrozi for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer - PharmExec

Jun 12, 2025
pulisher
Jun 12, 2025

'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals

Jun 12, 2025
pulisher
Jun 12, 2025

U.S. FDA Approves Nuvation Bio’s Ibtrozi - Contract Pharma

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Scores First FDA Nod With Oral Lung Cancer Drug - BioSpace

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtro - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer - PMLiVE

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Bio stock falls after FDA approves lung cancer drug By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC - The Pharma Letter

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Bio stock falls after FDA approves lung cancer drug - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Bio (NUVB) Gains FDA Approval for Lung Cancer Drug Ibtr - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Trading Halted Amidst Anticipated Announceme - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche - BioPharma Dive

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio’s IBTROZI Receives FDA Approval - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Set For First Launch With Ibtrozi In Lung Cancer - insights.citeline.com

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer Drug IBTROZI | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wed - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wedbush | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

# FDA approves Nuvation Bio’s lung cancer drug taletrectinib By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

US FDA approves Nuvation Bio’s lung cancer therapy - WSAU

Jun 11, 2025
pulisher
Jun 11, 2025

US FDA approves Nuvation Bio's rare lung cancer drug - Reuters

Jun 11, 2025
pulisher
Jun 11, 2025

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZ - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtrozi | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

# FDA approves Nuvation Bio’s lung cancer drug taletrectinib - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Trading Resumes | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung Cancer | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio scores first FDA approval for new lung cancer drug - Endpoints News

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation kinase inhibitor wins FDA approval in non-small cell lung cancer - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio stock in focus as FDA clears Ibtrozi (NUVB:NYSE) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio announces FDA approval of Ibtrozi for advanced ROS-1+ NSCLC - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

FDA Grants Approval to Nuvation Bio's Ibtrozi for Lung Cancer Treatment (NUVB) | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times

Jun 11, 2025
pulisher
Jun 11, 2025

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Mid Florida Newspapers

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Shares Surge Following FDA Approval | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

US FDA approves Nuvation Bio's lung cancer therapy - TradingView

Jun 11, 2025

Nuvation Bio Inc (NUVB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Nuvation Bio Inc (NUVB) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Sauvage Philippe
Chief Financial Officer
Jun 17 '25
Buy
1.79
4,000
7,160
9,902
Sauvage Philippe
Chief Financial Officer
Jun 16 '25
Buy
1.83
3,300
6,056
5,902
Sjogren Colleen
Chief Commercial Officer
Jun 16 '25
Buy
1.81
50,000
90,350
81,000
Wentworth Kerry
CHIEF REGULATORY OFFICER
Jun 16 '25
Buy
1.79
50,000
89,740
50,000
Hung David
PRESIDENT AND CEO
Jun 16 '25
Buy
1.79
500,000
893,500
59,281,054
Liu Dongfang
CHIEF MEDICAL OFFICER
May 02 '25
Option Exercise
1.94
20,000
38,800
32,000
Liu Dongfang
CHIEF MEDICAL OFFICER
May 02 '25
Sale
2.50
20,000
50,024
12,000
$20.66
price up icon 0.10%
$36.12
price up icon 0.17%
$21.00
price down icon 1.89%
$98.89
price down icon 1.86%
$107.07
price up icon 0.55%
biotechnology ONC
$241.18
price down icon 0.58%
大文字化:     |  ボリューム (24 時間):